Retrospective analysis of fatigue in men with metastatic castration-resistant prostate cancer treated with enzalutamide.

被引：1
|
作者：
Sridhar, Srikala S.
Smith, Alan D.
Fallah-Rad, Nazanin
Hansen, Aaron Richard
机构：
[1] Princess Margaret Canc Ctr, Toronto, ON, Canada
[2] Princess Margaret Hosp, Toronto, ON, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 06期
关键词：
D O I：
10.1200/JCO.2018.36.6_suppl.374
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
374
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Enzalutamide: A Review of Its Use in Metastatic, Castration-Resistant Prostate Cancer
    Sanford, Mark
    DRUGS, 2013, 73 (15) : 1723 - 1732
  • [42] Adherence to abiraterone or enzalutamide in elderly metastatic castration-resistant prostate cancer
    Banna, Giuseppe L.
    Urzia, Valeria
    Benanti, Chiara
    Pitre, Alessandra
    Lipari, Helga
    Di Quattro, Rosario
    De Giorgi, Ugo
    Schepisi, Giuseppe
    Basso, Umberto
    Bimbatti, Davide
    Rundo, Francesco
    Libra, Massimo
    Malatino, Lorenzo
    SUPPORTIVE CARE IN CANCER, 2020, 28 (10) : 4687 - 4695
  • [43] Adherence to abiraterone or enzalutamide in elderly metastatic castration-resistant prostate cancer
    Giuseppe L. Banna
    Valeria Urzia
    Chiara Benanti
    Alessandra Pitrè
    Helga Lipari
    Rosario Di Quattro
    Ugo De Giorgi
    Giuseppe Schepisi
    Umberto Basso
    Davide Bimbatti
    Francesco Rundo
    Massimo Libra
    Lorenzo Malatino
    Supportive Care in Cancer, 2020, 28 : 4687 - 4695
  • [44] Prognostic factors in men with metastatic castration-resistant prostate cancer treated with cabazitaxel
    Belderbos, Bodine P. S.
    de Wit, Ronald
    Oomen-de Hoop, Esther
    Nieuweboer, Annemieke
    Hamberg, Paul
    van Alphen, Robbert J.
    Bergman, Andre
    van der Meer, Nelly
    Bins, Sander
    Mathijssen, Ron H. J.
    van Soest, Robert J.
    ONCOTARGET, 2017, 8 (63) : 106468 - 106474
  • [45] Further analysis of PREVAIL: enzalutamide use in chemotherapy-naive men with metastatic castration-resistant prostate cancer
    Aragon-Ching, Jeanny B.
    ASIAN JOURNAL OF ANDROLOGY, 2014, 16 (06) : 803 - 804
  • [46] Enzalutamide: A Review of Its Use in Metastatic, Castration-Resistant Prostate Cancer
    Mark Sanford
    Drugs, 2013, 73 : 1723 - 1732
  • [47] Pembrolizumab in men with heavily treated metastatic castration-resistant prostate cancer (mCRPC).
    Tucker, Matthew D.
    Zhu, Jason
    Berry, William R.
    Ramalingam, Sundhar
    Zhang, Tian
    Harrison, Michael Roger
    Wu, Yuan
    Healy, Patrick
    George, Daniel J.
    Armstrong, Andrew J.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [48] Frailty and survival among veterans treated with abiraterone or enzalutamide for metastatic castration-resistant prostate cancer
    Deol, Ekamjit S.
    Sanfilippo, Kristen M.
    Luo, Suhong
    Fiala, Mark A.
    Wildes, Tanya
    Mian, Hira
    Schoen, Martin W.
    JOURNAL OF GERIATRIC ONCOLOGY, 2023, 14 (05)
  • [49] CARD: Overall survival (OS) analysis of patients with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel versus abiraterone or enzalutamide.
    Tombal, Bertrand F.
    Castellano, Daniel
    Kramer, Gero
    Eymard, Jean-Christophe
    De Bono, Johann S.
    Sternberg, Cora N.
    Fizazi, Karim
    Wulfing, Christian
    Bamias, Aristotelis
    Carles, Joan
    Iacovelli, Roberto
    Melichar, Bohuslav
    Sverrisdottir, Asgerdur
    Theodore, Christine
    Feyerabend, Susan
    Helissey, Carole
    Poole, Elizabeth
    Ozatilgan, Ayse
    Geffriaud-Ricouard, Christine
    De Wit, Ronald
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [50] Enzalutamide in Castration-Resistant Prostate Cancer Reply
    Hussain, Maha
    Saad, Fred
    Sternberg, Cora N.
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (14): : 1381 - 1381
12345